Inactive Instrument

Calendar Wilex AG Deutsche Boerse AG

Equities

DE0006614720

End-of-day quote Deutsche Boerse AG
- EUR - Intraday chart for Wilex AG

Chart calendar Wilex AG

72c7e70ae54665297411d148eb41c2ea.X_N_QyznFlvNGTNtM-eB9uNyLQC4-f-R3Yj1mvucjSw.JYU3LlzWYiH8X1JcHo3ktbRHe2GKprK85OSB17Do224IxSYQFcpyGKApag~3f2fe86979577b4df551c7f9ffb03c34

Upcoming events on Wilex AG

2024-07-27 GRC Natural Products and Bioactive Compounds Conference
2024-08-24 European Peptide Symposium
2024-08-31 Medicinal Chemistry International Symposium
2024-10-02 Q3 2024 Earnings Release (Projected)
2024-10-08 BIO Japan Conference
2024-10-10 02:00 am Q3 2024 Sales and Revenue Release - Interim Management Statement
2024-10-14 Festival of Biologics Conference
2024-10-19 HUPO World Congress
2024-11-03 World ADC San Diego Conference
2024-11-04 PEGS Europe Conference
2024-12-06 American Society of Hematology and Exposition Meeting
2025-07-09 Q2 2025 Earnings Release (Projected)

Past events on Wilex AG

2024-07-11 01:05 am Q2 2024 Earnings Release
2024-06-24 World ADC Asia Conference
2024-06-20 05:00 am Annual General Meeting
2024-06-03 Jefferies Global Healthcare Conference
2024-06-03 Antibody Engineering & Therapeutics Europe Conference
2024-06-02 BIO International Convention
2024-05-31 03:00 pm Oncology Innovation Forum
2024-05-31 11:45 am Oncology Innovation Forum - Panel
2024-05-31 11:45 am Oncology Innovation Forum - Panel
2024-05-30 American Society of Clinical Oncology Meeting
2024-05-20 ADC Payload Summit
2024-05-12 PEGS Boston Conference
2024-04-25 02:00 am Q1 2024 Sales and Revenue Release - Interim Management Statement
2024-04-23 10:00 am R&D Day
2024-04-15 Kempen Life Science Conference
2024-04-15 German Biotechnology Conference
2024-04-10 12:00 pm American Association for Cancer Research Meeting - Abstract No 7183
2024-04-08 12:00 pm American Association for Cancer Research Meeting - Abstract No 1865
2024-04-08 12:00 pm American Association for Cancer Research Meeting - Abstract No CT067
2024-04-07 04:30 pm American Association for Cancer Research Meeting - Abstract No :LB059

Annual results

Fiscal PeriodNovember 2019 2020 2021 2022 2023 2024
Net sales
Million EUR
Released
Forecast
Spread
7,96
8,63
-7.75%
9,58
9,70
-1.28%
2,31
2,31
0.13%
19,9
19,4
2.27%
16,8
13,8
21.75%

11,5

EBITDA
Million EUR
Released
Forecast
Spread
-9,60
-8,08
-18.83%
-17,6
-15,1
-16.55%
-24,8
-23,2
-7.14%
-16,4
-18,2
9.58%
-20,3
-31,1
34.63%

-22,1

EBIT
Million EUR
Released
Forecast
Spread
-10,1
-8,57
-18.4%
-18,3
-15,8
-15.97%
-25,6
-24,6
-4.27%
-17,2
-19,9
13.62%
-21,2
-32,0
33.72%

-22,6

Earnings before Tax (EBT)
Million EUR
Released
Forecast
Spread
-10,1
-8,30
-22.21%
-18,3
-14,9
-22.72%
-26,1
-24,7
-5.84%
-17,8
-20,3
12.29%
-20,3
0,00
-

0,00

Net income
Million EUR
Released
Forecast
Spread
-10,1
-8,30
-22.27%
-18,3
-14,9
-22.72%
-26,1
-24,9
-5.04%
-19,7
-20,0
1.67%
-20,3
0,00
-

0,00

EPS
EUR
Released
Forecast
Spread
-0,36
-0,30
-19.44%
-0,61
-0,54
-13.45%
-0,80
-0,72
-10.81%
-0,53
-0,64
17.46%
-0,44
-0,72
38.89%

-0,30

Announcement Date19/03/2025/03/2124/03/2205/03/2325/03/24-